Redeye interviews CEO Göran Forsberg about the new readout from trials in non-small cell lung cancer presented at ASCO 2023
Watch the interview hereDiTV interviews CEO Göran Forsberg about the promising interim efficacy results for nadunolimab in lung cancer to be presented at ASCO 2023
Watch the interview here
(R) = Regulatory press releases
”2023 is off to a very strong start with promising progress in our projects. I am convinced that Cantargia will maintain this positive development during the rest of the year, as we can look forward to additional results and start of new activities.”
CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden
E-mail: info@cantargia.com
Switch board: +46(0)46 2756260
Privacy Policy